JP2024511160A5 - - Google Patents

Info

Publication number
JP2024511160A5
JP2024511160A5 JP2023558760A JP2023558760A JP2024511160A5 JP 2024511160 A5 JP2024511160 A5 JP 2024511160A5 JP 2023558760 A JP2023558760 A JP 2023558760A JP 2023558760 A JP2023558760 A JP 2023558760A JP 2024511160 A5 JP2024511160 A5 JP 2024511160A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
antigen
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023558760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511160A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/021950 external-priority patent/WO2022204516A1/en
Publication of JP2024511160A publication Critical patent/JP2024511160A/ja
Publication of JP2024511160A5 publication Critical patent/JP2024511160A5/ja
Withdrawn legal-status Critical Current

Links

JP2023558760A 2021-03-26 2022-03-25 ヒト化ｍＡｂ１０７ Withdrawn JP2024511160A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163166711P 2021-03-26 2021-03-26
US63/166,711 2021-03-26
PCT/US2022/021950 WO2022204516A1 (en) 2021-03-26 2022-03-25 Humanized mab107

Publications (2)

Publication Number Publication Date
JP2024511160A JP2024511160A (ja) 2024-03-12
JP2024511160A5 true JP2024511160A5 (https=) 2025-04-02

Family

ID=83397925

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558760A Withdrawn JP2024511160A (ja) 2021-03-26 2022-03-25 ヒト化ｍＡｂ１０７

Country Status (7)

Country Link
US (1) US20240158511A1 (https=)
EP (1) EP4313112A4 (https=)
JP (1) JP2024511160A (https=)
CN (1) CN117355322A (https=)
AU (1) AU2022243562A1 (https=)
CA (1) CA3214962A1 (https=)
WO (1) WO2022204516A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026511370A (ja) * 2023-02-27 2026-04-14 カイジーン，インク． ヒト化抗ｃｄ１１ｂ抗体およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2399148A1 (en) * 2000-02-10 2001-08-16 Abbott Laboratories Antibodies that bind human interleukin-18 and methods of making and using
US10738121B2 (en) * 2015-02-27 2020-08-11 The General Hospital Corporation Therapeutic use of integrin-binding antibodies
CN107750255B (zh) * 2015-04-17 2022-08-30 安进研发（慕尼黑）股份有限公司 用于cdh3和cd3的双特异性抗体构建体
AU2016274175B2 (en) * 2015-06-12 2021-02-18 Mackay Medical Foundation The Presbyterian Church In Taiwan Mackay Memorial Hospital Methods and polypeptides for modulation of immunoresponse

Similar Documents

Publication Publication Date Title
CN107001459B (zh) 用于治疗炎症和自身免疫紊乱的抗age抗体
EP4198055A1 (en) Antibody of il-11 and use thereof
CN101842388B (zh) 针对β淀粉样肽的人源化抗体
MX2010011955A (es) Inmunoglobulinas de dominio variable doble y usos de las mismas.
JP2023511963A5 (https=)
WO2025016063A1 (zh) 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用
JPWO2018235247A1 (ja) 抗ｃｄ１０抗体
JP2024511160A5 (https=)
JP2024521638A5 (https=)
JP2023538518A5 (https=)
WO2023020624A1 (en) Use of alpha-enolase antagonist in treating fibrotic diseases
US10875918B2 (en) P2X7 receptor binders and polypeptides comprising the same
WO2024077987A1 (zh) Prdx1 IgG中和抗体及其制备方法和在制备急性器官损伤或脓毒症药物中的应用
TW201628647A (zh) 抗－ｉｌ４－ｉｌ１３雙特異性抗體
JP2023040241A5 (https=)
JP2024504370A5 (https=)
JP2023534779A5 (https=)
KR20240135698A (ko) 개파보바이러스 특이적 항체 cpv-b3 및 이를 포함하는 개파보바이러스 감염증 치료용 약제학적 조성물
EP3574020A1 (en) Antibodies to amyloid beta
CN118922442A (zh) 一种抗cd3抗体及其制备方法和用途
JP2023536653A5 (https=)
WO2020023619A2 (en) Blood brain barrier selective antibodies and methods of use
WO2023234406A1 (ja) カンナビノイド１型受容体に結合する抗体
RU2790561C2 (ru) Соединение, связывающее адреномедуллин (adm), для применения для терапии или профилактики симптомов заболевания
WO2026002062A1 (zh) 人源化抗α2δ1单克隆抗体及其应用